New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
04:55 EDTEXEL, EXEL, EXEL, AGIO, AGIO, AGIO, ALNY, ALNY, ALNY, EPZM, EPZM, EPZM, INFO, INFO, INFO, VRTX, VRTX, VRTX, FMI, FMI, FMIBernstein to hold a conference
Emerging Biotech Conference 2014 is being held in Snowbird, Utah on March 10-12.
News For EXEL;AGIO;ALNY;EPZM;INFO;VRTX;FMI From The Last 14 Days
Check below for free stories on EXEL;AGIO;ALNY;EPZM;INFO;VRTX;FMI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2014
18:19 EDTEXELExelixis announces 70% workforce reduction after trial failure
Exelixis said that as a result of the outcome of COMET-1, it will initiate a "significant" workforce reduction to enable the company to focus its financial resources on the late-stage clinical trials of cabozantinib in metastatic renal cell carcinoma and advanced hepatocellular carcinoma. The company will reduce its workforce by approximately 70%, or approximately 160 employees, resulting in approximately 70 remaining employees. Exelixis anticipates the one-time restructuring charge associated with the workforce reduction to be approximately $6M-$8M, with the majority to be completed by the end of Q4. As a result of this and other cost-saving measures contemplated, the company anticipates that it has sufficient cash to support its operations through the release of top-line results of the METEOR trial next year.
18:17 EDTEXELExelixis says COMET-1 phase 3 trial did not meet endpoint
Subscribe for More Information
August 31, 2014
14:04 EDTVRTXWorldwide Business Research to hold a conference
Subscribe for More Information
13:41 EDTAGIOCitigroup to hold a conference
Subscribe for More Information
August 27, 2014
08:02 EDTALNYAlnylam receives notice of allowance from USPTO for new patent
Subscribe for More Information
August 21, 2014
14:45 EDTEPZMNew Enterprise Associates reports 15.4% stake in Epizyme
Subscribe for More Information
09:16 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
August 20, 2014
08:07 EDTALNYAlnylam receives USPTO notice of allowance for new patent
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims in the Tuschl et al. patent application 13/725,262. The ’262 patent application includes newly allowed claims directed to compositions that mediate RNAi, and comprising a double-stranded molecule with up to 25 base pairs and at least one nucleotide analogue. Specifically, the newly allowed patent application broadly covers small interfering RNA molecules of various designs, including so-called “dicer substrate” RNAi triggers (Amarzguioui et al., Nat Protoc. 2006;1(2):508-17; Rose et al., Nucleic Acids Res. 2005 Jul 26;33(13):4140-56) and double-stranded, RNAi-mediating molecules containing moieties that include “unlocked nucleobase analogs” amongst other naturally or non-naturally occurring nucleotide analogues. The allowed claims of the Tuschl ’262 patent application, as well as other granted, Alnylam-owned or -licensed patents, in aggregate broadly cover compositions, methods, and uses of RNAi therapeutics.
August 19, 2014
15:50 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use